Stephen S. Chung

Southwestern Medical Center — United States

Medicine · Health Sciences

34h-index6.4kcitations253works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(97), Myeloproliferative Neoplasms: Diagnosis and Treatment(23), Aldose Reductase and Taurine(22), Hematopoietic Stem Cell Transplantation(21), Chemokine receptors and signaling(21)

Publications253 total

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
The origin of hepatocellular carcinoma depends on metabolic zonation
Science·2025· 3 cited
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial
Blood·2025· 1 citedOpen Access
IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease
Blood·2025Open Access
Outcomes in older adults (≥60 Years) with normal karyotype acute myeloid leukemia treated with intensive vs. lower-intensity chemotherapy: Path to a molecularly guided upfront treatment approach
Blood·2025
Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation
Blood·2025Open Access
Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents
JCO Oncology Practice·2025· 1 citedOpen Access
CD99 promotes self-renewal in hematopoietic stem cells and leukemia stem cells by regulating protein synthesis
Blood·2025· 3 citedOpen Access
Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines
Scientific Reports·2025· 2 citedOpen Access
TET2-Mutant Clonal Hematopoiesis Promotes Heart Failure With Preserved Ejection Fraction
Circulation·2025· 4 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Christopher Y. Park(10), Ben C.B. Ko(9), Sookja Kim Chung(9), Wenhuo Hu(6), Sookja Kim Chung(6), Jae H. Park(5), Omar Abdel‐Wahab(5), James Y. Yang(5), Sean M. Devlin(4), Young Rock Chung(4), Martin S. Tallman(4), Justin Taylor(4), Acy Lo(4), Yazan F. Madanat(4), Francine E. Garrett-Bakelman(3), Ross L. Levine(3), Ari Melnick(3), Eun Hee Kim(3), Virginia M. Klimek(3), Jenny Chau(3)